As of December 15, 2025, Cassava Sciences Inc (SAVA) reports a Net Margin of 76.70%.
Net Margin shows the share of revenue that becomes profit after all costs, reflecting overall profitability.
Comparing Cassava Sciences Inc's Net Margin to Peers
To better understand Cassava Sciences Inc's position, it's useful to compare its Net Margin against industry peers. Below are selected comparisons:
| Company | Net Margin |
|---|---|
| Cassava Sciences Inc (SAVA) | 76.70% |
| Royalty Pharma PLC (RPRX) | 37.95% |
| Zoetis Inc (ZTS) | 26.86% |
| Merck & Co Inc (MRK) | 26.68% |
| Eli Lilly and Co (LLY) | 23.51% |
| Johnson & Johnson (JNJ) | 15.84% |
Compared to its competitors, Cassava Sciences Inc's Net Margin is higher than all peers, suggesting strong overall cost management and pricing power.